Oragenics (NYSE:OGEN) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Performance

NYSE:OGEN opened at $0.40 on Wednesday. The firm’s 50-day moving average is $0.93 and its 200-day moving average is $1.26. The company has a market cap of $2.24 million, a price-to-earnings ratio of -0.05 and a beta of 0.50. Oragenics has a 52-week low of $0.40 and a 52-week high of $7.74.

Oragenics (NYSE:OGEN) last released its earnings results on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Institutional Investors Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC acquired a new stake in Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics at the end of the most recent quarter. Institutional investors and hedge funds own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.